Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Agarwal · SciRah

Researcher profile · Semantic Scholar

A. Agarwal

Share profile

A. Agarwal — researcher profile on SciRah

h-index: 21
Works: 92
Citations: 1,578

Most-cited papers

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
P. Moreau, A. Chanan-Khan, A. Roberts, A. Agarwal +15 more
2017Blood261 citations
Semantic Scholar
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Jonathan W. Friedberg, D. Mahadevan, Erin Cebula, D. Persky +9 more
2014Journal of Clinical Oncology210 citations Open access
Semantic Scholar
Monoclonal gammopathy of undetermined significance and Smoldering Multiple Myeloma: A review of the current understanding of epidemiology, biology, risk stratification and management of myeloma precursor disease
A. Agarwal, I. Ghobrial
2012Clinical Cancer Research89 citations Open access
Semantic Scholar
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
S. Jagannath, Yi Lin, H. Goldschmidt, D. Reece +13 more
2021Blood Cancer Journal79 citations Open access
Semantic Scholar
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
D. Siegel, G. Schiller, C. Samaras, M. Sebag +17 more
2020Leukemia76 citations Open access
Semantic Scholar
Alisertib (MLN8237) an Investigational Agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment
Wen-Qing Qi, C. Spier, Xiaobing Liu, A. Agarwal +5 more
2012Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis58 citations Open access
Semantic Scholar
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
K. Anderson, D. Auclair, S. Adam, A. Agarwal +46 more
2021Clinical Cancer Research49 citations Open access
Semantic Scholar
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
A. Thakurta, W. Pierceall, M. Amatangelo, Erin Flynt +1 more
2021OncoTarget48 citations Open access
Semantic Scholar
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
N. Stong, María Ortiz-Estévez, F. Towfic, M. Samur +6 more
2022Blood45 citations Open access
Semantic Scholar
Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
D. Siegel, G. Schiller, K. Song, R. Agajanian +14 more
2019British Journal of Haematology39 citations Open access
Semantic Scholar
Adverse outcome of human islet-allogeneic blood interaction1,2
T. Titus, P. Horton, L. Badet, A. Handa +5 more
2003Transplantation39 citations Open access
Semantic Scholar
American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce.
K. Winkfield, C. Flowers, J. Patel, Gladys Rodriguez +8 more
2017Journal of Clinical Oncology38 citations Open access
Semantic Scholar
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.
S. Jagannath, R. Abonour, B. Durie, M. Narang +11 more
2018Blood Advances35 citations Open access
Semantic Scholar
Heterogeneity of Second‐Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010–2016)
S. Jagannath, R. Abonour, B. Durie, C. Gasparetto +11 more
2018Clinical Lymphoma, Myeloma & Leukemia33 citations Open access
Semantic Scholar
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
W. Pierceall, M. Amatangelo, N. Bahlis, D. Siegel +9 more
2020Clinical Cancer Research32 citations Open access
Semantic Scholar
Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
N. Raje, D. Siegel, S. Jagannath, S. Lonial +12 more
202030 citations Open access
Semantic Scholar
Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
P. Moreau, A. Chanan-Khan, A. Roberts, A. Agarwal +12 more
201626 citations
Semantic Scholar
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis
S. Ailawadhi, S. Jagannath, Hans C. Lee, M. Narang +13 more
2020Cancer25 citations Open access
Semantic Scholar
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial
N. Bahlis, D. Siegel, G. Schiller, C. Samaras +16 more
2022Leukemia and Lymphoma24 citations Open access
Semantic Scholar
Connect MM Registry as a national reference for United States multiple myeloma patients
S. Ailawadhi, S. Jagannath, M. Narang, R. Rifkin +12 more
2019Cancer Medicine21 citations Open access
Semantic Scholar
Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)
R. Niesvizky, P. Richardson, Andrew J. Yee, A. Nooka +20 more
201621 citations
Semantic Scholar
Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.
C. Gasparetto, S. Jagannath, R. Rifkin, B. Durie +13 more
2021Clinical Lymphoma, Myeloma & Leukemia19 citations Open access
Semantic Scholar
Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.
S. Jagannath, R. Rifkin, C. Gasparetto, K. Toomey +14 more
2019Clinical Lymphoma, Myeloma & Leukemia19 citations Open access
Semantic Scholar
Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results
P. Moreau, A. Chanan-Khan, A. Roberts, A. Agarwal +15 more
201519 citations
Semantic Scholar
Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma
J. Rytlewski, D. Madduri, J. Fuller, T. Campbell +11 more
202018 citations Open access
Semantic Scholar
Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry
H. Terebelo, R. Abonour, Cristina J. Gasparetto, K. Toomey +11 more
2019British Journal of Haematology17 citations Open access
Semantic Scholar
Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
N. Shah, N. Munshi, J. Berdeja, S. Jagannath +6 more
2021Blood13 citations Open access
Semantic Scholar
KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.
S. Jagannath, Yi Lin, H. Goldschmidt, D. Reece +10 more
202013 citations
Semantic Scholar
Practical Considerations in Managing Relapsed Multiple Myeloma.
A. Agarwal, E. Chow, M. Bhutani, P. Voorhees +2 more
2017Clinical Lymphoma, Myeloma & Leukemia12 citations
Semantic Scholar
Novel Treatment Options for Waldenström’s Macroglobulinemia
H. Leblebjian, A. Agarwal, I. Ghobrial
2013Clinical Lymphoma, Myeloma & Leukemia12 citations Open access
Semantic Scholar
Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics
S. Sundararajan, Abhijeet Kumar, N. Korde, A. Agarwal
2016Current Hematologic Malignancy Reports10 citations
Semantic Scholar
Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.
P. Hari, B. Ung, S. Abouzaid, A. Agarwal +1 more
2019Future Oncology9 citations Open access
Semantic Scholar
Genetic and cytokine changes associated with symptomatic stages of CLL.
A. Agarwal, L. Cooke, Christopher Riley, Wen-Qing Qi +2 more
2014Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis9 citations
Semantic Scholar
Novel targeted therapies and combinations for the treatment of multiple myeloma.
A. Agarwal, D. Mahadevan
2013Cardiovascular & Haematological Disorders - Drug Targets9 citations
Semantic Scholar
Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma
A. Kansagra, Yi Lin, J. Berdeja, N. Shah +10 more
20208 citations Open access
Semantic Scholar
Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry
R. Abonour, R. Rifkin, C. Gasparetto, K. Toomey +12 more
2020British Journal of Haematology7 citations Open access
Semantic Scholar
Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry.
C. Gasparetto, R. Abonour, S. Jagannath, B. Durie +12 more
20177 citations
Semantic Scholar
P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
P. Rodríguez-Otero, N. Shah, N. Munshi, J. Berdeja +7 more
2022HemaSphere6 citations Open access
Semantic Scholar
Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
W. Pierceall, N. Bahlis, D. Siegel, G. Schiller +20 more
2018Blood6 citations Open access
Semantic Scholar
Daratumumab (Anti-CD38) interference with serological testing: An emerging challenge for blood banks in developing countries
Rasika Setia, Mitu Dogra, P. Sachdeva, A. Handoo +2 more
20176 citations Open access
Semantic Scholar
Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
Muhammad Husnain, S. Kurtin, Nikki L Barkett, I. Bin Riaz +1 more
2016Case Reports in Oncological Medicine6 citations Open access
Semantic Scholar
Hodgkin Variant of Richter’s Transformation in Chronic Lymphocytic Leukemia (CLL): An Illustrative Case Report and Literature Review
N. Gupta, Aditi Mittal, R. Duggal, T. Dadu +2 more
2021International Journal of Hematology-Oncology and Stem Cell Research5 citations Open access
Semantic Scholar
Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure
D. Siegel, G. Schiller, C. Samaras, M. Sebag +16 more
2018Blood5 citations Open access
Semantic Scholar
Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial
D. Siegel, G. Schiller, C. Samaras, M. Sebag +15 more
2020Blood4 citations
Semantic Scholar
Comprehensive Immune Profiling from Peripheral Blood and Bone Marrow in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Reflects Differences in Immune Subsets and Activation Status
G. Pietz, M. Tometsko, W. Copeland, E. Whalen +9 more
2018Blood4 citations Open access
Semantic Scholar
Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
P. Moreau, A. Chanan-Khan, A. Roberts, A. Agarwal +13 more
20164 citations
Semantic Scholar
Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
C. Touzeau, A. Chanan-Khan, A. Roberts, A. Agarwal +13 more
20154 citations
Semantic Scholar
Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study
N. Raje, David S. Siegel, S. Jagannath, S. Lonial +12 more
20213 citations Open access
Semantic Scholar
Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.
S. Manier, A. Kansagra, L. Anderson, J. Berdeja +14 more
20213 citations
Semantic Scholar
Health-Related Quality of Life Assessments Predict Relapse or Death in Patients with Newly Diagnosed Multiple Myeloma (MM): Results from the Connect® MM Registry
I. Wagner, B. Durie, Sundar Jagannath, M. Narang +11 more
20183 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Jagannath×16
Invite
S. Jagannath — researcher profile on SciRah
D. Siegel×11
Invite
D. Siegel — researcher profile on SciRah
R. Abonour×10
Invite
R. Abonour — researcher profile on SciRah
B. Durie×10
Invite
B. Durie — researcher profile on SciRah

×10

Invite

M. Narang — researcher profile on SciRah

H. Terebelo×10

Invite

H. Terebelo — researcher profile on SciRah

Invite

K. Toomey — researcher profile on SciRah

Invite

R. Rifkin — researcher profile on SciRah

Invite

D. Reece — researcher profile on SciRah

S. Srinivasan×9

Invite

S. Srinivasan — researcher profile on SciRah

Amani Kitali×9

Invite

Amani Kitali — researcher profile on SciRah

Invite

P. Moreau — researcher profile on SciRah